Current Cancer Drug Targets
Title:Meet Our Editorial Board Member
Volume: 20 Issue: 6
Author(s): M.P. Carty
Affiliation:
Export Options
About this article
Cite this article as:
Carty M.P. , Meet Our Editorial Board Member, Current Cancer Drug Targets 2020; 20 (6) . https://dx.doi.org/10.2174/156800962006200707220550
DOI https://dx.doi.org/10.2174/156800962006200707220550 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
18
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Caring for HIV-Infected Patients in the ICU in The Highly Active Antiretroviral Therapy Era
Current HIV Research First-in-human Phase 1 CRISPR Gene Editing Cancer Trials: Are We Ready?
Current Gene Therapy Trabectedin as a New Chemotherapy Option in the Treatment of Relapsed Platinum Sensitive Ovarian Cancer
Current Pharmaceutical Design The Role of Iron Chelation in Cancer Therapy
Current Medicinal Chemistry Aspartic Protease Inhibitors as Potential Anti-Candida albicans Drugs: Impacts on Fungal Biology, Virulence and Pathogenesis
Current Medicinal Chemistry Hypertension and Angiogenesis
Current Pharmaceutical Design CBP-dependent Wnt/β-catenin signaling is crucial in regulation of MDR1 transcription
Current Cancer Drug Targets Three-Dimensional Tissue Models for Drug Discovery and Toxicology
Recent Patents on Biotechnology Understanding FOXO, New Views on Old Transcription Factors
Current Cancer Drug Targets De Novo Malignancies After Organ Transplantation: Focus on Viral Infections
Current Molecular Medicine microRNAs in Cancer: Lessons from Melanoma
Current Pharmaceutical Design Identification of AHSA1 as a Potential Therapeutic Target for Breast Cancer: Bioinformatics Analysis and <i>in vitro</i> Studies
Current Cancer Drug Targets Advances of Paclitaxel Formulations Based on Nanosystem Delivery Technology
Mini-Reviews in Medicinal Chemistry Nanotechnology-based Drug Delivery Systems as Potential for Skin Application: A Review
Current Medicinal Chemistry Biomedical Applications of Zinc Oxide Nanomaterials
Current Molecular Medicine Acronycine Derivatives: A Promising Series of Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry The Association of Chemotherapy and Radiotherapy in Squamous Cell Carcinoma of Anal Canal
Current Drug Therapy Targeting Receptor Tyrosine Kinase Pathways in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Development of New Drugs that Act Through Membrane Receptors and Involve an Action of Inverse Agonism
Recent Patents on CNS Drug Discovery (Discontinued) Generation of Human Single-chain Antibody to the CD99 Cell Surface Determinant Specifically Recognizing Ewing’s Sarcoma Tumor Cells
Current Pharmaceutical Biotechnology